Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Sep 14, 2011

166_ip_2011-09-14_3cdf925d-e86e-45ac-a8e2-5057d7de9390.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

UBS Best of Germany Conference

September 14, 2011

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Achieving Profitable Growth in Attractive Health Care Segments

Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE & Co. KGaA

Fresenius Group: Financial Results

5-year CAGR: 10%

EBIT5-year CAGR: 14%

Net Income5-year CAGR: 19%

Group financial results before APP-transaction-related special items

Fresenius Group: Financial Results

S
l
a
e
s		 E
B
I
T		 1
N
i
t
e
n
c
o
m
e
/
H
1
1
1		 €
8
0
0
4
m
,		 €
1
2
0
7
m
,		 €
3
6
3
m
G
h
t
t
t
t
r
o
a
c
o
n
s
a
n
w
t
c
r
r
e
n
c
r
a
e
s
u
y		 %
6		 1
1
%		 2
2
%
G
h
l
t
t
t
r
o
w
a
a
c
u
a
t
c
u
r
r
e
n
c
y
r
a
e
s		 %
4		 8
%		 %
2
0

1Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Group: Financial Results by Business Segment

/
H
1
1
1		 F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 F
i
r
e
s
e
n
u
s
K
b
i
a		 F
i
r
e
s
e
n
u
s
H
l
i
e
o
s		 F
i
r
e
s
e
n
u
s
V
d
a
m
e
S
l
a
e
s
G
h
t
r
o
w		 \$
U
S
6
2
3
0
m
,
%
7		 €
1
9
7
1
m
,
%
1
3		 €
1
2
9
3
m
,
%
6		 €
3
1
3
m
%
7
-
E
B
I
T
G
h
t
r
o
w		 \$
U
S
9
5
5
m
%
7		 €
4
1
1
m
%
1
8		 €
1
2
3
m
%
1
2		 €
1
2
m
%
2
0
-

Fresenius Medical Care: Update H1/11

    • Strong operating results – despite the impact of the new prospective U.S. Medicare payment system
    • Dialysis products:
  • Excellent sales growth of 17% cc in Asia-Pacific
  • Dialysis services prospective payment system rule for Medicare patients
  • -1.8% increase in dialysis reimbursement for 2012
  • 3.1% transition adjustment eliminated for 2012
  • Further expansion of global network acquisitions of
  • International Dialysis Centers (IDC) in Europe
  • -Liberty Dialysis Holdings, Inc. in the U.S.
  • American Access Care Holdings, LLC in the U.S.

Fresenius Kabi: Update H1/11

    • Excellent organic sales growth of 13%; 100 bps EBIT margin increase to 20.9%
  • 16% organic sales growth in Emerging Markets
  • representing 28% of total Kabi sales
  • China 20% growth, mainly attributable to parenteral nutrition
    • 22% organic sales growth in North America (Q2: 11%) driven by new products and continued drug shortages
  • FY/11 8% organic sales outlook within 7 10% mid-term guidance range, H2/11 yoy growth expected at low to mid single-digit rates

Sales Split / Organic Growth by Region

Fresenius Helios: Update H1/11

  • 4% organic sales growth fully in line with guidance; 50 bps EBIT margin increase to 9.5%
  • Further revival of hospital privatization activity – ~15 projects YTD pending/concluded
  • Includes 4 larger projects (€100 – 200 million revenue each)
  • Rottweil hospital consolidated as of July 1
  • Excellent progress at Krefeld hospital
  • 6% admission CAGR 08–10
  • Construction phase I (654-bed building) completed on schedule; total investment of €180 million (2008 to 2014)

Maximum care hospital Krefeld (>1,000 beds) Construction phase I Construction phase II

Fresenius Vamed: Update H1/11

    • H1/11 sales and EBIT on track, but negative growth rates due to Ukraine project in H1/10
    • Full-year 2011 sales and EBIT growth guidance revised – Middle East/North Africa unrest leading to project delays in H2/11
    • Continued sales/earnings growth opportunities following the temporary project delays
  • -€164 million order intake in H1/11
    • Expect significant increase in order intake in H2/11

Fresenius Biotech: Update H1/11

Removab:

  • -29% sales growth to €1.8 million
  • Launched in Austria, France, Germany, Scandinavia, UK; obtained reimbursement approval in Italy in July
  • Three-hour vs. six-hour infusion recommended by CHMP1 – facilitates use in out-patient setting
  • 1-year survival rate fourfold in Removab-treated patients vs. control group (11.4% vs. 2.6%)2; CHMP recommendation allows marketing of survival data

ATG:

  • 9% sales growth to €12.8 million
  • First company in Germany with approval in stem cell transplantation; received approval in Austria in June

EBIToutlook 2011 of -€30 million confirmed

UBS Best of Germany Conference, Fresenius SE & Co. KGaA, Investor Relations © Copyright, September 14, 2011 Page 11 1 CHMP (EMA's Committee for Medicinal Products for Human Use); 2 Follow-up results for the pivotal study Removab (catumaxomab) – trifunctional antibody; ATG Fresenius S – immunsuppressive agent

Fresenius Group: 2011 Outlook Raised or Fully Confirmed

P
i
r
e
v
o
u
s		 N
e
w
S
l
h
t
a
e
s
g
r
o
w
N
i
t
e
n
c
o
m
e		 \$
b
U
S
1
3
0
n
>
\$
U
S
1,
0
7
0
1,
0
9
0
m
–		 d
f
i
c
o
n
r
m
e
f
i
d
c
o
n
r
m
e
S
l
h
t
a
e
s
g
r
o
w
E
B
I
T
i
m
a
r
g
n		 %
i
5
o
r
g
a
n
c
>
1
9
2
0
%
–		 %
i
8
o
r
g
a
n
c
~
2
0
%
~
S
l
h
t
a
e
s
g
r
o
w
E
B
I
T		 3
%
i
5
o
r
g
a
n
c
–
€
2
5
0
2
6
0
m
–		 f
i
d
c
o
n
r
m
e
€
2
6
0
m
~
S
l
h
t
a
e
s
g
r
o
w
E
B
I
T
h
t
g
r
o
w		 %
5
1
0
–
0
%
5
1
–		 %
0
5
–
0
%
5
–
E
B
I
T		 €
3
0
m
~
-		 f
i
d
c
o
n
r
m
e

"_" upper half of range

Fresenius Group: 2011 Outlook Raised or Fully Confirmed

P
i
r
e
o
s
v
u		 N
e
w
R
h
t
e
v
e
n
u
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 8
%
7
–		 f
i
d
c
o
n
r
m
e
1
N
i
h
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 2
%
1
1
6
–		 8
%
1
5
1
–
C
a
p
e
x		 %
f
G
l
5
o
r
o
u
p
s
a
e
s
~		 f
i
d
c
o
n
r
m
e

1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Group: Where are we Heading Mid term?

Additional growth through small / mid-sized acquisitions

Focus on quality and cost leadership

Mid-term stretch financial goal: Group net income >€1 bn by 2014

Attachments

Fresenius Group: Profit and Loss Statement

G
h
t
t
r
o
a
c
o
w		 t
t
t
n
s
a
n
r
a
e
s
€
m		 /
Q
2
1
1		 /
H
1
1
1		 /
Q
2
1
1		 /
H
1
1
1
S
l
a
e
s		 4
0
4
2
,		 8
0
0
4
,		 %
6		 %
6
E
B
I
T		 6
3
2		 1
2
0
7
,		 %
8		 %
1
1
N
i
t
t
t
e
n
e
r
e
s		 1
4
1
-		 2
7
6
-		 %
1
0
-		 %
1
-
I
t
n
c
o
m
e
a
x
e
s		 1
5
3
-		 2
8
8
-		 9
%
-		 1
1
%
-
1
N
i
t
e
n
c
o
m
e		 1
9
3		 3
6
3		 %
1
0		 %
2
2

1 Net income attributable to Fresenius SE & Co. KGaA and before special items due to MEB and CVR accounting

Fresenius Group: Cash Flow

€
m		 /
Q
2
1
1		 L
T
M
i
M
a
r
g
n		 /
Q
2
1
0		 L
T
M
i
M
a
r
g
n		 G
h
t
r
o
w
Y
Y
o
O
i
C
h
F
l
t
p
e
r
a
n
g
a
s
o
w		 3
7
2		 8
%
1
0		 3
6
7		 8
%
1
1		 %
1
C
(
)
t
a
p
e
x
n
e		 1
4
5
-		 4
3
%
-		 1
9
0
-		 4
6
%
-		 2
4
%
C
F
h
F
l
r
e
e
a
s
o
w
(
)
b
f
i
i
i
d
d
i
i
d
d
t
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 2
2
7		 %
6
5		 1
7
7		 %
7
1		 %
2
8
(
)
A
i
i
i
t
t
c
q
u
s
o
n
s
n
e		 9
5
7
-		 6
5
-
i
i
d
d
D
e
n
s
v		 8
8
2
-		 2
7
2
-		 %
6
C
F
h
F
l
r
e
e
a
s
o
w
(
)
f
i
i
i
d
d
i
i
d
d
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 6
5
8
-		 %
3
1
-		 1
6
0
-		 %
3
5

Cash Flow Development LTM

€
m		 O
p
e
r
a		 i
C
F
t
n
g		 C
a
p
e
x		 (
)
t
n
e		 1
F
C
h
F
l
r
e
e
a
s
o
w
/
L
T
M
H
1
1
1		 i
L
T
M
M
a
r
g
n		 /
L
T
M
H
1
1
1		 i
L
T
M
M
a
r
g
n		 /
L
T
M
H
1
1
1		 i
L
T
M
M
a
r
g
n
8
3
5		 0
%
1
5		 (
)
8
2
1		 (
)
%
4
7		 0
4
1		 0
3
%
1
2
9
9		 %
1
1
5		 (
)
1
1
7		 (
)
%
4
5		 1
8
2		 3
%
7
0
9
1		 2
8
%		 (
)
7		 (
)
0
%
1		 2
1		 %
1
7
Co
/
te
rp
or
a
O
he
t
r		 3
9
-		 /
n
a		 (
)
1
6		 /
n
a		 5
5
-		 /
n
a
l.
F
M
C
ex
c		 8
2
6		 2
2
8
%
1		 (
)
3
2
2		 (
)
%
4
5		 0
5
4		 2
8
3
%
G
ro
up		 1
7
5
6
,		 %
1
0
8		 (
)
7
0
5		 (
)
%
4
3		 1
0
5
1
,		 %
6
5

Margin = in % of sales

1 Before Acquisitions and Dividends

2 Incl. FMC dividend

3 Understated: 9.3% excluding €58 million of Capex commitments from acquisitions

Fresenius Group: Debt and Interest Ratios

Debt excludes Mandatory Exchangeable Bonds

Fresenius Kabi: Strong Organic Sales Growth

€
m		 /
H
1
1
1		 /
H
1
1
0		 O
i
r
g
a
n
c
G
h
t
r
o
w
I
f
i
T
h
n
u
s
o
n
e
r
a
p
y		 3
4
4		 2
4
1		 %
5
I.
V
D
r
u
g
s		 3
2
7		 0
6
7		 2
%
4
C
l
i
i
l
N
i
i
t
t
n
c
a
u
r
o
n		 5
6
0		 5
1
2		 9
%
d
i
l
i
/
M
D
e
c
a
e
v
c
e
s
T
f
i
T
h
l
r
a
n
s
u
s
o
n
e
c
n
o
o
g
y		 2
3
6		 2
1
4		 %
9
l
l
T
t
o
a
s
a
e
s		 1
9
7
1
,		 1
7
4
5
,		 %
1
3

Fresenius Kabi: Strong Organic Sales Growth

€
m		 /
H
1
1
1		 /
H
0
1
1		 O
i
r
g
a
n
c
G
h
t
r
o
w
E
u
r
o
p
e		 9
0
9		 8
3
6		 7
%
N
h
A
i
t
o
r
m
e
r
c
a		 9
5
1		 4
4
5		 2
2
%
i
i
f
i
A
P
s
a
a
c
c
-		 3
3
2		 2
7
9		 %
1
9
i
i
/
f
i
L
A
A
t
a
n
m
e
r
c
a
r
c
a		 2
1
1		 1
8
5		 %
1
2
T
l
l
t
o
a
s
a
e
s		 9
1
7
1
,		 1
7
4
5
,		 3
%
1

Fresenius Kabi: Excellent EBIT Growth

€
m		 /
H
1
1
1		 /
H
1
1
0		 G
h
t
r
o
w
E
r
o
p
e
u
M
i
a
r
g
n		 1
9
1
2
1.
0
%		 8
1
7
2
1.
3
%		 %
7
h
i
N
A
t
o
r
m
e
r
c
a
M
i
a
r
g
n		 2
0
0
3
8.
5
%		 1
3
8
3
1.
0
%		 %
4
5
/
/
A
i
P
i
f
i
L
i
A
i
A
f
i
t
s
a
a
c
c
a
n
m
e
r
c
a
r
c
a
-
M
i
a
r
g
n		 1
0
4
1
9.
2
%		 8
1
1
7.
5
%		 2
8
%
C
d
C
R
D
t
t
&
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 8
4
-		 0
5
-		 8
%
6
-
T
l
E
B
I
T
t
o
a		 4
1
1		 3
4
7		 8
%
1
M
i
a
r
g
n		 2
0
9
%		 1
9
9
%

Fresenius Helios: Excellent Sales and EBIT Growth

€
m		 /
H
1
1
1		 /
H
1
1
0		 G
h
t
r
o
w
T
l
l
t
o
a
s
a
e
s		 1
2
9
3
,		 1
2
2
3
,		 %
6
E
B
I
T
E
b
l
i
h
d
l
i
i
f
l
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o
M
i
a
r
g
n		 1
2
4
9.
7
%		 1
1
0
9.
0
%		 %
1
3
i
i
i
A
t
c
q
u
s
o
n
s
(
)
l
i
d
i
t
1
c
o
n
s
o
a
o
n
y
r
<		 1
-		 0
T
l
E
B
I
T
t
o
a		 1
2
3		 1
1
0		 %
1
2
i
M
a
r
g
n		 9
5
%		 9
0
%

Fresenius Helios: 2010 Restructuring Plan

i
f
l
i
Y
t
e
a
r
s
n
p
o
r
o
o
1
<		 1 2 3 4 5 5
>		 l
T
t
o
a
f
l
i
i
N
o.
o
c
n
c
s		 - - 6 4 7 - 2
5		 4
2
(
)
R
€
e
e
n
e
m
v
u		 - - 1
8
6		 2
6
1		 1
7
5		 - 1,
6
0
7		 2,
2
2
9
T
t
a
r
g
e
(
)
E
B
I
T
D
A
i
%
m
a
r
g
n		 - 3.
0		 6.
0		 9.
0		 1
2.
0		 1
5.
0		 1
5.
0
(
)
E
B
I
T
D
A
€
m		 - - 1
1.
2		 2
3.
5		 2
0.
9		 - 2
4
1.
1		 2
9
6.
7
R
d
t
e
p
o
r
e
(
)
%
E
B
I
T
D
A
i
m
a
r
g
n		 - - 4.
0		 1
0.
8		 1
1.
9		 - 1
5.
8		 1
3.
9
(
)
E
B
I
T
D
A
€
m		 - - 7.
5		 2
8.
2		 2
0.
8		 - 2
5
4.
2		 3
1
0.
7
f
l
i
i
N
t
t
o.
o
c
n
c
s
a
r
g
e
>		 - - 3 3 4 - 1
4		 2
4
f
l
i
i
N
t
t
o.
o
c
n
c
s
a
r
g
e
<		 - - 3 1 3 - 1
1		 1
8

Fresenius Helios: Performance Indicators

/
H
1
1
1		 /
H
1
1
0		 C
h
a
n
g
e
1
N
f
h
i
l
t
o
o
o
s
p
a
s
l
i
i
A
t
c
u
e
c
a
r
e
c
n
c
s
-
l
i
i
P
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 6
3
4
3
2
0		 6
2
4
2
2
0		 %
2
%
2
%
0
1
f
b
d
N
o
o
e
s
A
l
i
i
t
c
u
e
c
a
r
e
c
n
c
s
-
l
i
i
P
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 1
8
9
0
4
,
1
5,
4
3
7
3,
4
6
7		 1
8
5
6
4
,
1
5,
0
9
7
3,
4
6
7		 %
2
%
2
%
0
2
d
i
i
A
m
s
s
o
n
s
(
)
A
i
i
t
t
t
c
u
e
c
a
r
e
n
p
a
e
n
-		 3
2
1
4,
7
4		 3
2,
0
5
7
0		 %
4
2
O
c
c
u
p
a
n
c
y
P
t-
t
o
s
a
c
e
c
a
r
e
u
-		 7
9
%		 8
0
%
2
(
)
A
l
h
f
d
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s
A
t
c
u
e
c
a
r
e
-
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 6.
7
2
9.
6		 6.
9
2
9.
9

Dec 31, 2010

2Clinics in Germany

Fresenius Vamed: Sales and EBIT in Line with Expectations

€
m		 /
H
1
1
1		 /
H
1
1
0		 G
h
t
r
o
w
P
j
b
i
t
r
o
e
c
s
n
e
s
s
u
b
S
i
i
e
r
v
c
e
u
s
n
e
s
s		 2
0
2
1
1
1		 2
3
0
1
0
8		 2
%
1
-
%
3
T
l
l
t
o
a
s
a
e
s		 3
3
1		 3
3
8		 %
7
-
T
l
E
B
I
T
t
o
a
i
M
a
r
g
n		 1
2
3.
8
%		 1
5
%
4
4		 %
2
0
-
1
O
d
i
k
t
r
e
r
n
a
e
1
O
d
b
k
l
r
e
r
a
c
o
g		 1
6
4
2
7
6		 3
2
8
2
8
0
1		 0
%
5
-
%
5
-

1Project business only

2Dec 31, 2010

Financial Calendar

  • 02.11.2011 Report on 1st 3rd quarter 2011
  • 21.02.2012 Report on Fiscal Year 2011
  • 03.05.2012 Report on 1st quarter 2012
  • 11.05.2012 Annual General Meeting, Frankfurt/Main
  • 01.08.2012 Report on 1st half 2012
  • 31.10.2012 Report on 1st 3rd quarter 2012

Contact

  • Birgit Grund SVP Investor Relations Fresenius SE & Co. KGaA
  • Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.